A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.

MLA

Gradishar, William J., et al. “A Double-Blind, Randomised, Placebo-Controlled, Phase 2b Study Evaluating Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with HER2-Negative Advanced Breast Cancer.” European Journal of Cancer (Oxford, England : 1990), vol. 49, no. 2, Jan. 2013, pp. 312–22. EBSCOhost, https://doi.org/10.1016/j.ejca.2012.08.005.

APA

Gradishar, W. J., Kaklamani, V., Sahoo, T. P., Lokanatha, D., Raina, V., Bondarde, S., Jain, M., Ro, S. K., Lokker, N. A., & Schwartzberg, L. (2013). A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. European Journal of Cancer (Oxford, England : 1990), 49(2), 312–322. https://doi.org/10.1016/j.ejca.2012.08.005

Chicago

Gradishar, William J, Virginia Kaklamani, Tarini P Sahoo, Dasappa Lokanatha, Vinod Raina, Shailesh Bondarde, Minish Jain, Sunhee Kwon Ro, Nathalie A Lokker, and Lee Schwartzberg. 2013. “A Double-Blind, Randomised, Placebo-Controlled, Phase 2b Study Evaluating Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with HER2-Negative Advanced Breast Cancer.” European Journal of Cancer (Oxford, England : 1990) 49 (2): 312–22. doi:10.1016/j.ejca.2012.08.005.